Samsung Biologics Wins Backing For $1.8B PolyPeptide Buy
By Irene Madongo ( November 2, 2026, 3:29 PM GMT) -- Samsung Biologics said Monday it has provisionally secured nearly all the backing of shareholders of PolyPeptide Group in a public tender offer to acquire the drug manufacturer for an estimated 1.46 billion Swiss francs ($1.8 billion)....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.